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Abstract Urotensin II (UII), a cyclic neuropeptide, functions
not only in the central nervous system but also in non-neural
systems including cardiovascular systems. In the present study we
examined whether UII regulates hypertrophy in cardiomyocytes.
The exposure of cultured cardiomyocytes from neonatal rats to
UII dose-dependently activated extracellular signal-regulated
kinases (ERKs), important molecules in the development of
cardiac hypertrophy. ERK activation by UII at 100 nM peaked
at 8 min after stimulation. UII markedly induced expression of
specific genes encoding atrial natriuretic peptide and brain
natriuretic peptide, and significantly increased amino acid
incorporation into proteins. Incubation of cardiomyocytes with
UII increased cell size and myofibril organisation. UII, then,
might participate in cardiomyocyte hypertrophy. ß 2001 Fed-
eration of European Biochemical Societies. Published by Else-
vier Science B.V. All rights reserved.
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1. Introduction
Cardiac hypertrophy is not only an adaptational state pre-
ceding cardiac failure but also an independent risk factor for
cardiac morbidity and mortality [1]. Therefore, it is even more
important to determine the molecular mechanism of the de-
velopment of cardiac hypertrophy. Mechanical stretch is an
initiating factor for cardiac hypertrophy in response to haemo-
dynamic overload [2,3]. Additionally, a number of neuro-
humoral factors such as angiotensin II (AngII), endothelin 1
(ET-1), and catecholamines are reported to be associated with
development of hypertrophy [4^8].
Urotensin II (UII), a cyclic neuropeptide originally isolated
from the ¢sh spinal cord [9], recently has been detected and
found to be functionally implicated in mammalian central
nervous and cardiovascular systems [10^12]. In the cardiovas-
cular system, many reports indicated that UII might regulate
arterial blood pressure as a potent vasoactive ‘somatostatin-
like’ peptide [9^13]. Low concentrations of UII produced re-
laxations, while higher concentrations induced contraction of
vascular smooth muscle [9]. UII also can increase or decrease
myocardial contractility, depending on dose [11]. Moreover,
UII administration to human subjects induced ST segment
changes in the electrocardiogram observed in myocardial is-
chemia [11]. Actions of UII in mammals are proposed to be
mediated through interactions with certain somatostatin re-
ceptor subtypes [9]. Recently an orphan human G protein-
coupled receptor (GPR) homologous to rat GPR14 has
been found to be expressed predominantly in cardiovascular
tissues and to function as a receptor for UII [11]. Taken
together, such evidence strongly suggests that UII may in£u-
ence cardiovascular homeostasis as well as pathologic process-
es such as ischemic heart disease and heart failure. However,
whether UII is involved in the regulation of cell enlargement
has not been reported. We therefore examined the role of UII
in the development of cardiomyocyte hypertrophy, and found
that this peptide induces hypertrophic responses in cardio-
myocytes of neonatal rats.
2. Materials and methods
2.1. Cell culture
Primary cultures of cardiac myocytes were prepared from ventricles
of 1-day-old Wistar rats as described previously [4,7] according to the
method of Simpson [14]. In brief, cardiomyocytes were plated at a
¢eld density of 1U105 cells/cm2 on 35-mm culture dishes with 2 ml of
Dulbecco’s modi¢ed Eagle’s medium (DMEM) (Gibco BRL) with
10% foetal bovine serum (FBS). 24 h after seeding, the culture me-
dium was changed to DMEM with 0.1% FBS for another 48 h before
treatment with UII (human) (Peptide Institute, Osaka, Japan).
2.2. Assay for kinase activation
The activities of extracellular signal-regulated kinases (ERKs) were
measured using myelin basic protein (MBP)-containing gels as de-
scribed previously [4,7]. In brief, after stimulation with UII, cells
were lysed with bu¡er A (25 mM Tris^HCl at pH 7.4, 25 mM
NaCl, 1 mM sodium orthovanadate, 10 mM sodium pyrophosphate,
10 nM okadaic acid, 0.5 mM EGTA, and 1 mM phenylmethylsulfonyl
£uoride). Cell lysates were electrophoresed on a sodium dodecyl sul-
phate (SDS)^polyacrylamide gel containing 0.5 mg/ml MBP. ERK in
the gels was denatured in 6 M guanidine HCl and renatured in 50 mM
Tris^HCl at pH 8.0 containing 0.04% Triton X-100 and 5 mM
2-mercaptoethanol. Phosphorylation activities of ERK were assayed
by incubating the gels with [Q-32P]ATP (Du Point-New England Nu-
clear). After incubation the gels were washed extensively, dried and
processed for autoradiography.
2.3. [3H]Phenylalanine incorporation
Protein synthesis was determined by assessing the incorporation of
labelled phenylalanine from the extracellular medium into total tri-
chloroacetic acid-precipitable cell proteins [4,7]. Cardiac myocytes cul-
tured for 24 h in DMEM with 10% FBS were starved in 0.1% FBS^
DMEM for 24 h. Then, UII or saline was added into the medium and
the cells were further cultured for 24 h. [3H]phenylalanine (1 WCi/ml)
(Du Point-New England Nuclear Co.) was added 2 h before harvest.
At the end of the labeling incubation, plates were placed on ice,
quickly washed twice with ice-cold phosphate-bu¡ered saline, incu-
bated for 30 min with 10% trichloroacetic acid, and washed again.
Precipitates were solubilised for 30 min in 1 M NaOH and neutral-
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ised. Total radioactivity was measured by a liquid scintillation coun-
ter.
2.4. Northern blot analysis
Total RNA of cultured cardiomyocytes was extracted using zol B
(Cinna Biotecx Laboratories). Total RNA (10 Wg) was size-fraction-
ated electrophoretically in 1.2% formaldehyde agarose gels and trans-
ferred to nylon membranes (Millipore). Blots were hybridised with
[K-32P]dCTP (Du Pont-New England Nuclear)-labelled cDNA frag-
ments of sequences encoding atrial natriuretic peptide (ANP) and
brain natriuretic peptide (BNP). Hybridised bands were quantitated
by a densitometer.
2.5. Immunocytochemistry
Cardiomyocytes cultured on glass cover slides were ¢xed for 20 min
in 4% paraformaldehyde and permeabilised for 10 min in 0.1% Triton
X-100. The cells were incubated with phalloidin-tetramethylrhod-
amine isothiocyanate (TRITC) and 4P,6-diamidino-2-phenylindole di-
hydrochloride (DAPI) (Sigma) for 1 h at 37‡C [15].
2.6. Statistical analysis
Statistical comparison was carried out within three independent
experiments using one-way ANOVA and Dunnett’s t-test. Values of
P6 0.05 were considered to indicate statistical signi¢cance.
3. Results and discussion
3.1. Activation of kinases by UII in cardiac myocytes
A growing body of evidence has shown that stimuli that
induce hypertrophy activate multiple intracellular protein ki-
nases and phosphatases leading to reprogramming of gene
expression and a consequent increase in protein synthesis in
cardiac myocytes [3,16]. Mitogen-activated protein kinases
(MAPK) have been reported to play important roles in the
development of cardiac hypertrophy [3,16]. ERKs, which are
members of the MAPK family, have been extensively inves-
tigated [3,17^21]. To elucidate the role of UII in cardiac hy-
pertrophy, we ¢rst examined whether UII induces activation
of ERKs in cultured cardiac myocytes. ERKs in cardiac myo-
cytes were slightly activated by UII at 1 nM and strongly
activated by UII at 100 nM (Fig. 1A and C), representing
dose-dependent activation of ERKs. At 100 nM the increase
Fig. 1. Activation of ERKs by UII in cultured cardiomyocytes. Car-
diomyocytes were incubated with UII at the indicated concentration
for 8 min (A) or at 100 nM for the indicated period of time (B).
Aliquots of the cell lysates were electrophoresed on an SDS^polyac-
rylamide gel containing 0.5 mg/ml MBP. After denaturation and re-
naturation we assayed phosphorylation activity of ERKs by incu-
bating the gel with [Q-32P]ATP. Then the gel was washed, dried and
processed for autoradiography. Representative autoradiograms are
shown. C: Quantitative analysis of ERK activity. The intensities of
the 42-kDa ERK band were measured by densitometric scanning of
the autoradiograms. The activity was expressed relative to that of
the 42-kDa ERK obtained from unstimulated cardiomyocytes. The
data are indicated as a mean of two experiments. ERK, extracellu-
lar signal-regulated kinase; UII, urotensin II; SDS, sodium dodecyl
sulphate; MBP, myelin basic protein.
Fig. 2. Induction of expression of ANP and BNP genes by UII in
cardiac myocytes. Cardiomyocytes were incubated with 100 nM UII
or saline (control) for 2 h. Total RNA (10 Wg) was size-fractionated
in 1.2% formaldehyde agarose gels. Expression of ANP and BNP
genes was examined by Northern analysis. Ethidium bromide stain-
ing of 18S ribosomal RNA is presented to con¢rm integrity of
RNA. A: Representative autoradiograms from three independent
experiments are shown. B: The intensities of ANP, BNP or 18S
bands were measured by densitometric scanning of the autoradio-
grams. The ratio of relative amounts of ANP or BNP to that of
18S are shown. Data are presented as mean þ S.E.M. from three in-
dependent experiments. *P6 0.05 versus control. ANP, atrial natri-
uretic peptide; BNP, brain natriuretic peptide; UII, urotensin II.
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in activation of ERKs was rapid with a slight increase at 2 min
and a peak at 8 min followed by a decrease (Fig. 1B and C).
The results suggest that UII can rapidly induce signi¢cant
activation of ERKs in cardiac myocytes.
3.2. Expression of speci¢c genes by cardiac myocytes in
response to UII
Induction of speci¢c gene expression is one of the responses
of cardiomyocytes that cause hypertrophy [16]. Notably these
genes include foetal genes such as ANP and BNP genes and
they have been reported to be increased in the development of
cardiac hypertrophy [16]. Activation of ERKs also has been
reported to be involved in the expression of ANP and BNP
genes [18,22]. We therefore examined whether UII induces
increases in the expression of these two foetal type genes.
Exposure of cardiac myocytes to UII for 2 h signi¢cantly
increased expression of ANP and BNP genes beyond expres-
sion in control cells (Fig. 2A and B). The results suggest that
UII stimulation results in induction of foetal type gene ex-
pression in cardiac myocytes.
Fig. 3. Protein synthesis stimulated by UII in cardiac myocytes.
Cardiac myocytes starved in DMEM with 0.1% FBS for 24 h were
treated with 100 nM UII or saline (control) for 24 h, and then were
pulse-labelled with [3H]phenylalanine (1 WCi/ml) for the ¢nal 2 h.
Incorporation of [3H]phenylalanine into the acid-precipitable cellular
fraction was determined by liquid scintillation counting. Data are
presented as means þ S.E.M. from three independent experiments
(control = 100%). *P6 0.05 versus control. UII, urotensin II.
Fig. 4. UII-induced morphologic changes of cardiac myocytes. A: Cultured cardiac myocytes were exposed to saline (a and c) or to UII (b and
d) at 100 nM for 24 h and then incubated with phalloidin-TRITC (red) and DAPI (blue). Representative stained preparation from three inde-
pendent experiments are shown. a and b, U200; c and d, U400. B: Relative cardiomyocyte size. Surface area of cardiomyocytes was measured
by using NIH Image software in 60 randomly chosen cells from three di¡erent dishes. Data are presented as mean þ S.E.M. *P6 0.05 versus
saline. C: Numbers of cardiomyocytes with well-organised myo¢laments were counted in whole dish. Data are presented as mean þ S.E.M.
from three di¡erent dishes. *P6 0.05 versus saline. UII, urotensin II; TRITC, tetramethylrhodamine isothiocyanate; DAPI, 4P,6-diamidino-2-
phenylindole dihydrochloride.
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3.3. UII-induced protein synthesis in cardiac myocytes
Activation of protein kinases and induction of speci¢c gene
expression can lead to increases in protein synthesis in cardiac
myocytes [3,16]. [3H]Phenylalanine incorporation from the
extracellular medium into the total trichloroacetic acid-precip-
itable cell protein has been one method used to determine the
protein synthesis rate [7]. When we examined UII-induced
protein synthesis by assessing UII-induced incorporation of
phenylalanine into total protein of cardiac myocytes, addition
of UII for 24 h signi¢cantly accelerated protein synthesis com-
pared to control cells incubated with saline (P6 0.05) (Fig. 3).
3.4. UII-induced morphologic changes in cardiac myocytes
Enhanced sarcomere organisation is a feature of cardio-
myocyte hypertrophy [16] that we were able to observe in
response to UII (Fig. 4A^C). Control cells incubated with
saline for 24 h were small and irregularly shaped (Fig. 4Aa),
and myo¢laments were poorly organised (Fig. 4Ac). When the
cells were incubated with UII for 24 h, they became larger
(Fig. 4Ab), and myo¢laments were well organised (Fig. 4Ad).
These results suggest that increased cell size and myo¢brillar
organisation induced by UII accompanies the synthesis of new
proteins.
The cyclic neuropeptide UII not only in£uences neuromus-
cular function but also participates in cardiovascular regula-
tion [9^13]. We showed in the present study that UII is able to
induce hypertrophic responses in cardiac myocytes including
activation of ERKs, induction of foetal type gene expression,
increases in protein synthesis and morphologic changes. The
mechanism by which UII induces cardiomyocyte hypertrophy
are unclear at present. Recently, UII has been reported to
exert its e¡ects on cardiovascular function through GPR14
[11], and an increase in inositol phosphates [23]. A quite re-
cent report demonstrated that UII induced contraction, actin
stress ¢bre formation and proliferation in arterial smooth
muscle cells through the small GTPase RhoA and Rho kinase
[24]. Since the Rho family is involved in the activation of
ERKs and development of hypertrophy in cardiac myocytes
[25,26], UII may induce ERK activation and cardiac hyper-
trophy through Rho family proteins. Otherwise, UII elevates
intracellular Ca2 levels [11], and Ca2 and Ca2-binding pro-
teins, such as Ca2/calmodulin-dependent protein kinases and
calcineurin, have been reported to regulate the development of
cardiac hypertrophy induced by AngII, ET-1 and catechol-
amines [8,15,27], UII may, therefore, also need participation
of Ca2/Ca2-binding proteins to induce cellular events in
cardiac myocytes. Further studies are necessary to issue these
hypotheses.
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